Molecule intelOpportunity: ModerateEssentialCrowded market

Ondansetron

280 brands · 109 companies · product forms

ATC: A04AA01

Opportunity snapshot

Launch attractiveness
35
Market saturation
100
Price room
100
Regulatory risk
0
280
brands
109
companies
Rs 1,380.93
median price
363
price points
115.14x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 3%

Price room

Across observed sources and strengths
CheapestRs 85.47
MedianRs 1,380.93
Most expensiveRs 9,841.16
Spread115.14×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 115.14x across 363 trusted points (Rs 85.47-9841.16). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Ondansetron — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(0) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

109 canonical companies and 280 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 115.14x across 363 trusted points (Rs 85.47-9841.16). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.